450,144 research outputs found
Hereditary Breast and Ovarian cancer study Netherlands (HEBON)
No full textHereditary Breast and Ovarian cancer study Netherlands (HEBON) we enrolled members of high risk families tested for BRCA1/2 mutations. With this study we actively participate in two international initiatives, the prospective International BRCA1/2 Carrier Cohort Study (IBCCS, coordinated at NKI) and the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA, epidemiologic part, coordinated at NKI). Biological samples, DNA of women. N=2700
Hereditary Breast and Ovarian cancer study Netherlands (HEBON)
No full textHereditary Breast and Ovarian cancer study Netherlands (HEBON) we enrolled members of high risk families tested for BRCA1/2 mutations. With this study we actively participate in two international initiatives, the prospective International BRCA1/2 Carrier Cohort Study (IBCCS, coordinated at NKI) and the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA, epidemiologic part, coordinated at NKI). Biological samples, DNA of women. N=2700
Hereditary Breast and Ovarian cancer study Netherlands (HEBON)
No full textHereditary Breast and Ovarian cancer study Netherlands (HEBON) we enrolled members of high risk families tested for BRCA1/2 mutations. With this study we actively participate in two international initiatives, the prospective International BRCA1/2 Carrier Cohort Study (IBCCS, coordinated at NKI) and the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA, epidemiologic part, coordinated at NKI). Biological samples, DNA of women. N=2700
Hereditary Breast and Ovarian cancer study Netherlands (HEBON)
No full textHereditary Breast and Ovarian cancer study Netherlands (HEBON) we enrolled members of high risk families tested for BRCA1/2 mutations. With this study we actively participate in two international initiatives, the prospective International BRCA1/2 Carrier Cohort Study (IBCCS, coordinated at NKI) and the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA, epidemiologic part, coordinated at NKI). Biological samples, DNA of women. N=2700
Hereditary Breast and Ovarian cancer study Netherlands (HEBON)
No full textHereditary Breast and Ovarian cancer study Netherlands (HEBON) we enrolled members of high risk families tested for BRCA1/2 mutations. With this study we actively participate in two international initiatives, the prospective International BRCA1/2 Carrier Cohort Study (IBCCS, coordinated at NKI) and the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA, epidemiologic part, coordinated at NKI). Biological samples, DNA of women. N=2700
Hereditary Breast and Ovarian cancer study Netherlands (HEBON)
No full textHereditary Breast and Ovarian cancer study Netherlands (HEBON) we enrolled members of high risk families tested for BRCA1/2 mutations. With this study we actively participate in two international initiatives, the prospective International BRCA1/2 Carrier Cohort Study (IBCCS, coordinated at NKI) and the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA, epidemiologic part, coordinated at NKI). Biological samples, DNA of women. N=2700
Hereditary Breast and Ovarian cancer study Netherlands (HEBON)
No full textHereditary Breast and Ovarian cancer study Netherlands (HEBON) we enrolled members of high risk families tested for BRCA1/2 mutations. With this study we actively participate in two international initiatives, the prospective International BRCA1/2 Carrier Cohort Study (IBCCS, coordinated at NKI) and the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA, epidemiologic part, coordinated at NKI). Biological samples, DNA of women. N=2700
Hereditary Breast and Ovarian cancer study Netherlands (HEBON)
No full textHereditary Breast and Ovarian cancer study Netherlands (HEBON) we enrolled members of high risk families tested for BRCA1/2 mutations. With this study we actively participate in two international initiatives, the prospective International BRCA1/2 Carrier Cohort Study (IBCCS, coordinated at NKI) and the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA, epidemiologic part, coordinated at NKI). Biological samples, DNA of women. N=2700
Going Beyond Counting First Authors in Author Co-citation Analysis
Get PDFThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
The UN-SUSTAINABLE Match in HCV Recipients. Evidences from the Italian D-MELD Study on Balancing Donor-Recipient Risk Factors
No full textThe UN-SUSTAINABLE Match in HCV Recipients. Evidences from the Italian D-MELD Study on Balancing Donor-Recipient Risk Factor
- …
